Adam Golda
Overview
Explore the profile of Adam Golda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allahabadi H, Amann J, Balot I, Beretta A, Binkley C, Bozenhard J, et al.
IEEE Trans Technol Soc
. 2022 Dec;
3(4):272-289.
PMID: 36573115
This article's main contributions are twofold: 1) to demonstrate how to apply the general European Union's High-Level Expert Group's (EU HLEG) guidelines for trustworthy AI in practice for the domain...
2.
Poterala-Hejmo A, Golda A, Pacholczyk M, Student S, Tylki-Szymanska A, Lalik A
Int J Mol Sci
. 2020 Jul;
21(14).
PMID: 32664626
Perturbations of glycosaminoglycan metabolism lead to mucopolysaccharidoses (MPS)-lysosomal storage diseases. One type of MPS (type VI) is associated with a deficiency of arylsulfatase B (ARSB), for which we previously established...
3.
Golda A, Jurecka A, Gajda K, Tylki-Szymanska A, Lalik A
Mol Genet Metab Rep
. 2016 Mar;
3:11-7.
PMID: 26937388
Background: Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive lysosomal disorder caused by a deficient activity of N-acetylgalactosamine-4-sulfatase (ARSB). Pulmonary hypertension (PH) occurs in MPS VI patients and is...
4.
Jurecka A, Lugowska A, Golda A, Czartoryska B, Tylki-Szymanska A
J Appl Genet
. 2014 Dec;
56(2):205-10.
PMID: 25472774
The aim of this study was to determine the prevalence rates of mucopolysaccharidoses in Poland and to compare them with other European countries. A retrospective epidemiological survey covering the period...
5.
Jurecka A, Zakharova E, Cimbalistiene L, Gusina N, Malinova V, Rozdzynska-Swiatkowska A, et al.
Pediatr Int
. 2013 Dec;
56(4):520-5.
PMID: 24373060
Background: The aim of this study was to describe the natural clinical course, incidence and prevalence of mucopolysaccharidosis type VI (MPS VI) in Russia, Kazakhstan, and Central and Eastern Europe....
6.
Jurecka A, Zakharova E, Cimbalistiene L, Gusina N, Kulpanovich A, Golda A, et al.
Am J Med Genet A
. 2013 May;
161A(6):1291-9.
PMID: 23633437
Mucopolysaccharidosis type VI (MPS VI) is a rare lysosomal, autosomal recessive storage disorder caused by deficient activity of N-acetylgalactosamine-4-sulfatase (ARSB). Approximately, 140 ARSB gene mutations have been identified; however, most...
7.
Golda A, Jurecka A, Opoka-Winiarska V, Tylki-Szymanska A
Int J Cardiol
. 2012 Jun;
167(1):1-10.
PMID: 22704873
Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) is an inborn error of metabolism, with incidences at birth ranging from 1 in 1.5 million to 1 in 43,000 live births. This...
8.
Jurecka A, Golda A, Opoka-Winiarska V, Piotrowska E, Tylki-Szymanska A
Mol Genet Metab
. 2011 Sep;
104(4):695-9.
PMID: 21917494
We present here the first literature description of a predominantly cardiac phenotype in a patient homozygous for missense mutation p.R152W in the N-acetylogalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. An adult Caucasian...
9.
Golda A, Jurecka A, Tylki-Szymanska A
Int J Cardiol
. 2011 Jul;
158(1):6-11.
PMID: 21737154
The aim of the article is to gather and summarize the published data about the incidence, course of illness, treatment possibilities and complications of cardiovascular disorders in patients with mucopolysaccharidosis...
10.
Kowalczyk J, Francuz P, Swoboda R, Lenarczyk R, Sredniawa B, Golda A, et al.
Nephron Clin Pract
. 2010 May;
116(2):c114-22.
PMID: 20502047
Aim: This study evaluated the impact of hyperuricemia (HUR) on outcome in patients with different types of impaired renal function (IRF) and acute myocardial infarction (AMI) treated invasively. Methods: Out...